首页|18F-Florbetapir PET定量标准化Centiloid及其在中国临床前期阿尔茨海默病队列中的应用

18F-Florbetapir PET定量标准化Centiloid及其在中国临床前期阿尔茨海默病队列中的应用

Standardization of amyloid quantitation with 18F-Florbetapir SUV ratio to the Centiloid scale and its application in Chinese Preclinical Alzheimer's Disease Study

扫码查看
目的 建立18F-氟贝他吡(Florbetapir)PET图像的SUV比值(SUVR)标准化Centiloid(CL)的公式,并研究中国临床前期阿尔茨海默病(AD)(C-PAS)队列的β-淀粉样蛋白(Aβ)沉积情况.方法 利用统计参数图(SPM)12对"Standard PIB"和"Florbetapir Calibration"公开数据库中的11C-匹兹堡化合物B(PIB)和18F-Florbetapir图像进行预处理,得到SUVR标准化为CL的变换公式.回顾性纳入C-PAS队列于2018年10月至2023年8月在复旦大学附属华山医院核医学/PET中心接受18F-Florbetapir PET检查的受试者942例[男357例、女585例,年龄(66.4±8.1)岁],计算其CL值并分析AD、轻度认知障碍(MCI)和认知未受损(CU)组的Aβ阳性率[CL值≤12为Aβ阴性,12<CL值<30为Aβ弱阳性,CL值≥30为Aβ阳性].使用Kruskal-Wallis秩和检验、Dunn's检验(Bonferroni法校正)和x2检验对数据进行统计分析.结果 18F-Florbetapir PET图像的SUVR标准化CL的计算公式为 CL=179.64×SUVR_Florbetapir-186.95.在 C-PAS 队列中,AD 组的 SUVR、CL 值和 Aβ 阳性率(含弱阳性)分别为 1.29±0.22、43.97±39.23 和 71.80%(140/195);MCI 组的 SUVR、CL 值和 Aβ(含弱阳性)阳性率分别为 1.04(1.02,1.14)、1.16(-4.04,17.14)和 28.50%(61/214);CU 组的 SUVR、CL 值和阳性率分别为 1.04(1.01,1.08)、0.54(-5.29,7.69)和 15.38%(82/533);3 组的 SUVR、CL 值和 Aβ 沉积阴性/弱阳性/阳性比例的差异均有统计学意义(H=148.30,H=148.30,x2=262.12,均P<0.001).此外,混合型MCI较非遗忘型MCI表现出更高的CL值[2.45(-1.54,46.32)与-1.58(-6.33,7.20);H=8.21,P=0.016;z=2.81,P=0.015]和 Aβ 阳性率(含弱阳性)[41.18%(14/34)与 14.64%(6/41);x2值:12.71和10.63,均P<0.01];CU组的CL值和Aβ阳性率随年龄增长而增加.结论 本研究验证了18F-Florbetapir PET图像计算CL值的可行性,并揭示了 C-PAS队列中Aβ沉积情况,为国内开展多中心Aβ PET研究奠定了基础.
Objective To standardize the quantitation of 18F-Florbetapir PET SUV ratio(SUVR)to the Centiloid(CL)scale,and analyze the positive rate of β-amyloid(Aβ)in Chinese Preclinical Alzheimer's Disease(AD)Study(C-PAS).Methods 11C-Pittsburgh compound B(PIB)and 18F-Florbetapir images from public databases"Standard PIB"and"Florbetapir Calibration"were preprocessed by statistical para-metric mapping(SPM)12,and the transformative formulas from SUVR to CL were derived.Then a total of 942 subjects(357 males,585 females;age(66.4±8.1)years)from C-PAS who received 18F-Florbetapir PET at the Department of Nuclear Medicine & PET Center,Huashan Hospital,Fudan University from October 2018 to August 2023 were retrospectively included.CL values were calculated and the Aβ positive rates(CL value≤ 12,Aβ negative;12<CL value<30,Aβ subtle pathology;CL value≥30,Aβ positive)of AD,mild cognitive impairment(MCI)and cognitive unimpaired(CU)groups were explored.Data were analyzed by using Kruskal-Wallis rank sum test,Dunn's test(Bonferroni correction)and x2 test.Results The formula for the 18F-Florbetapir SUVR converted to CL was CL=179.64xSUVR_Florbetapir-186.95.In the C-PAS cohort,the SUVR,CL value,Aβ positive rate(including subtle pathology)of patients with clinically diag-nosed AD were 1.29±0.22,43.97±39.23,71.80%(140/195),which were 1.04(1.02,1.14),1.16(-4.04,17.14),28.50%(61/214)for patients with MCI,and 1.04(1.01,1.08),0.54(-5.29,7.69),15.38%(82/533)for CU subjects,respectively.SUVR,CL value and the ratio of negative,subtle and positive Aβpathology of the above three groups exhibited statistical differences(H=148.30,H=148.30,x2=262.12,all P<0.001).Besides,mixed MCI group exhibited higher CL values((2.45(-1.54,46.32)vs-1.58(-6.33,7.20);H=8.21,P=0.016;z=2.81,P=0.015)and Aβ positive rate(including subtle pathology)(41.18%(14/34)vs 14.64%(6/41);x2 values:12.71 and 10.63,both P<0.01),compared to non-amnestic MCI group.The CL values and Aβ positive rates were also increased with age in CU group.Conclusion This study validates the feasibility of the CL formula with 18F-Florbetapir images and reveals Aβ deposition in C-PAS cohort,which can lay the foundation for multi-center Aβ PET studies in China.

Alzheimer diseaseCognitive dysfunctionAmyloid beta-peptidesEthylene glycolsThiazolesPositron-emission tomography

黄琪、任树华、管一晖、崔亮、黄琳、郭起浩、谢芳

展开 >

复旦大学附属华山医院核医学/PET中心,上海 200030

上海交通大学附属第六人民医院老年科,上海 200030

阿尔茨海默病 认知功能障碍 淀粉样β肽类 乙二醇类 噻唑类 正电子发射断层显像术

国家自然科学基金

82201583

2024

中华核医学与分子影像杂志
中华医学会

中华核医学与分子影像杂志

CSTPCD北大核心
影响因子:1.107
ISSN:2095-2848
年,卷(期):2024.44(5)
  • 22